ANAPTYSBIO, INC. Payments to Acquire Debt Securities, Available-for-sale
ANAPTYSBIO, INC. (ANAB) reported Payments to Acquire Debt Securities, Available-for-sale of $4.96 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-09-21
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $4.96M, a 90.86% decline year-over-year.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $19.66M, a 61.72% decline year-over-year.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $196.41M, a 48.36% decline from fiscal 2024.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $380.38M, a 25.16% increase from fiscal 2023.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $303.92M, a 62.13% decline from fiscal 2022.
- ANAPTYSBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $802.50M, a 576.29% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.96M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $4.96M 10-KT · filed 2026-09-21 | $4.96M derived: sum of 3 quarters · filed 2026-09-21 | $24.61M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-09-21 | $19.66M derived: sum of 3 quarters · filed 2026-09-21 | $73.86M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $19.66M derived: sum of 2 quarters · filed 2026-09-21 | $73.86M derived: sum of 3 quarters · filed 2026-09-21 | $196.41M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $19.66M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $73.86M derived: sum of 2 quarters · filed 2026-09-21 | $196.41M 10-Q · filed 2025-11-04 | $317.29M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $54.21M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $176.75M 10-KT · filed 2026-09-21 | $297.64M derived: sum of 3 quarters · filed 2026-09-21 | $348.98M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $122.55M 10-Q · filed 2026-05-12 | $243.43M derived: sum of 2 quarters · filed 2026-09-21 | $294.77M derived: sum of 3 quarters · filed 2026-09-21 | $443.93M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $120.88M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $172.23M derived: sum of 2 quarters · filed 2026-09-21 | $321.38M derived: sum of 3 quarters · filed 2026-09-21 | $380.38M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $51.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $200.50M derived: sum of 2 quarters · filed 2025-11-04 | $259.49M 10-Q · filed 2025-11-04 | $325.80M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $149.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $208.15M 10-Q · filed 2025-08-06 | $274.46M derived: sum of 3 quarters · filed 2026-03-03 | $344.50M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $59.00M 10-Q · filed 2025-05-05 | $125.30M derived: sum of 2 quarters · filed 2026-03-03 | $195.35M derived: sum of 3 quarters · filed 2026-03-03 | $314.36M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $66.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $136.35M derived: sum of 2 quarters · filed 2026-03-03 | $255.36M derived: sum of 3 quarters · filed 2026-03-03 | $303.92M 10-K · filed 2026-03-03 |
| 2023-09-30 | $70.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $189.06M derived: sum of 2 quarters · filed 2024-11-05 | $237.61M 10-Q · filed 2024-11-05 | $365.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $119.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $167.56M 10-Q · filed 2024-08-05 | $295.14M derived: sum of 3 quarters · filed 2025-02-27 | $475.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $48.55M 10-Q · filed 2024-05-09 | $176.13M derived: sum of 2 quarters · filed 2025-02-27 | $356.26M derived: sum of 3 quarters · filed 2025-02-27 | $528.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $127.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $307.71M derived: sum of 2 quarters · filed 2025-02-27 | $480.03M derived: sum of 3 quarters · filed 2025-02-27 | $802.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $180.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $352.45M derived: sum of 2 quarters · filed 2023-11-02 | $674.92M 10-Q · filed 2023-11-02 | $767.11M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $172.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $494.80M 10-Q · filed 2023-08-07 | $586.98M derived: sum of 3 quarters · filed 2024-03-11 | $603.72M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $322.48M 10-Q · filed 2023-05-11 | $414.66M derived: sum of 2 quarters · filed 2024-03-11 | $431.40M derived: sum of 3 quarters · filed 2024-03-11 | $434.90M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $92.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $108.93M derived: sum of 2 quarters · filed 2024-03-11 | $112.42M derived: sum of 3 quarters · filed 2024-03-11 | $118.66M 10-K · filed 2024-03-11 |
| 2021-09-30 | $16.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $20.24M derived: sum of 2 quarters · filed 2022-11-08 | $26.48M 10-Q · filed 2022-11-08 | $64.84M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $9.73M 10-Q · filed 2022-08-08 | $48.09M derived: sum of 3 quarters · filed 2023-03-01 | $117.71M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.24M 10-Q · filed 2022-05-04 | $44.59M derived: sum of 2 quarters · filed 2023-03-01 | $114.22M derived: sum of 3 quarters · filed 2023-03-01 | $127.15M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $38.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $107.98M derived: sum of 2 quarters · filed 2023-03-01 | $120.91M derived: sum of 3 quarters · filed 2023-03-01 | $194.93M 10-K · filed 2023-03-01 |
| 2020-09-30 | $69.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $82.56M derived: sum of 2 quarters · filed 2021-11-04 | $156.57M 10-Q · filed 2021-11-04 | $233.34M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | $12.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $86.95M 10-Q · filed 2021-08-09 | $163.71M derived: sum of 3 quarters · filed 2022-03-07 | $206.45M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | $74.01M 10-Q · filed 2021-05-04 | $150.78M derived: sum of 2 quarters · filed 2022-03-07 | $193.51M derived: sum of 3 quarters · filed 2022-03-07 | $246.06M derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | $76.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $119.50M derived: sum of 2 quarters · filed 2022-03-07 | $172.05M derived: sum of 3 quarters · filed 2022-03-07 | $251.81M 10-K · filed 2022-03-07 |
| 2019-09-30 | $42.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $95.29M derived: sum of 2 quarters · filed 2020-11-04 | $175.05M 10-Q · filed 2020-11-04 | $398.59M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $52.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $132.31M 10-Q · filed 2020-08-10 | $355.86M derived: sum of 3 quarters · filed 2021-02-25 | $389.44M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $79.76M 10-Q · filed 2020-05-06 | $303.31M derived: sum of 2 quarters · filed 2021-02-25 | $336.89M derived: sum of 3 quarters · filed 2021-02-25 | $395.10M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $223.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $257.13M derived: sum of 2 quarters · filed 2021-02-25 | $315.33M derived: sum of 3 quarters · filed 2021-02-25 | $347.54M 10-K · filed 2021-02-25 |
| 2018-09-30 | $33.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $91.79M derived: sum of 2 quarters · filed 2019-11-08 | $124.00M 10-Q · filed 2019-11-08 | $304.20M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $58.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $90.41M 10-Q · filed 2019-08-08 | $270.62M derived: sum of 3 quarters · filed 2020-03-02 | $291.96M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $32.20M 10-Q · filed 2019-05-07 | $212.41M derived: sum of 2 quarters · filed 2020-03-02 | $233.75M derived: sum of 3 quarters · filed 2020-03-02 | $296.11M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $180.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $201.55M derived: sum of 2 quarters · filed 2020-03-02 | $263.90M derived: sum of 3 quarters · filed 2020-03-02 | $290.90M 10-K · filed 2020-03-02 |
| 2017-09-30 | $21.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $83.70M derived: sum of 2 quarters · filed 2018-11-08 | $110.70M 10-Q · filed 2018-11-08 | $110.70M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $62.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $89.35M 10-Q · filed 2018-08-07 | $89.35M derived: sum of 3 quarters · filed 2019-02-28 | $89.35M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $27.00M 10-Q · filed 2018-05-08 | $27.00M derived: sum of 2 quarters · filed 2019-02-28 | $27.00M derived: sum of 3 quarters · filed 2019-02-28 | $27.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $0.00 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |